Previous Next

ARCHIVE

№4' 2021

ONCOLOGY

International Medical Journal, Vol. 27., Iss. 4, 2021, P. 42−49.


DOI (https://doi.org/10.37436/2308-5274-2021-4-8)

CONCOMITANT IMMUNE THERAPY IN ONCOLOGY PRACTICE


Prokhach N. E., Sorochan P. P., Polozova M. V., Hromakova I. A., Kuzmenko O. V.

SP "Grigoriev Institute of Medical Radiology and Oncology, National Academy of Medical Sciences of Ukraine", Kharkiv, Ukraine

Radiation and polychemotherapy significantly affect the immune system of a cancer patient, unabling to adequately respond to infectious agents and provide effective antitumor protection. Rehabilitation of immune disorders is an urgent task, the solution of which will contribute to the generalization of experience when suing the immune modulators in cancer patients. To summarize the existing data on the use of concomitant immune therapy in antitumor treatment, the reports published within 30 years in Pubmed, Cochrane Library, ScienceDirect and the Vernadsky National Library of Ukraine were analyzed. It is expedient to use immune correction at different stages of antitumor treatment in the case of compliance with certain criteria for the prescribing the immune modulatory drugs. Their use is most justified after the primary tumor removal, even in the presence of metastases, because the increase in antitumor resistance is achieved in the absence of tumor cells in the patient's body or their presence in minimal quantities. Possibilities and goals of concomitant immune therapy in cancer patients should be considered taking into account the stage of treatment. Immune modulators with additional properties (detoxification, antioxidant) can serve as universal drugs. In the early post−surgery period, it is advisable to use the drugs, affecting the cells of the mononuclear phagocyte system for the prevention of postoperative infectious complications. During radiation and chemotherapy, preference should be given to the drugs with antitoxic effects and capable of preventing the leukopenia development. Thus, the prescribing of concomitant immune therapy in the combined treatment of cancer patients is an important task, demanding a balanced approach.

Key words: immune therapy, immune modulators, quality of life, cancer patients.


REFERENCES


1. Novikov V. I., Vlasov A. A. Primenenie immunokorrektsii v lechenii opukholei molochnoi zhelezy // Vyatskii meditsinskii vestn. 2016. T. 51, № 3. S. 8−15.

2. Khaitov R. M., Pinegin B. V. Mekhanizm deistviya i klinicheskoe primenenie immunomodulyatorov // Allergologiya, astma i klinicheskaya immunologiya. 2003. № 8. S. 43−49.

3. Pinegin B. V., Pashchenkov M. V. Immunostimulyatory muramilpeptidnoi prirody v lechenii i profilaktike infektsionno−vospalitel'nykh protsessov // Immunologiya. 2019. T. 40, № 3. S. 65−71. doi: 10.24411/0206−4952−2019−13007

4. Muramyl dipeptide mediated activation of human bronchial epithelial cells interactin with basophils: a novel mechanism of airway inflammation / H. N. Qiu et al. // Clinical and Experimental Immunology. 2013. № 172. P. 81−94. doi: 10.1111/cei.12031

5. Anderson P. M. Immune therapy for sarcomas // Advances in Experimental Medicine and Biology. 2017. № 995. P. 127−140. doi: 10.1007/978−3−319−53156−4_6

6. Mifamurtide for the treatment of nonmetastatic teosarcoma. / K. Ando et al. // Expert Opinion on Pharmacotherapy. 2011. Vol. 12, № 2. P. 285−292. doi: 10.1517/14656566.2011.543129.

7. Khaitov R. M. Immunomodulyatory: mify i real'nost' // Immunologiya. 2020. T. 41, № 2. S. 103−106. doi: 10.33029/0206−4952−2020−41−2−101−106

8. Pinegin B. V., Khaitov R. M. Sovremennye printsipy sozdaniya immunotropnykh lekarstvennykh preparatov // Immunologiya. 2019. T. 40, № 6. S. 57−62. doi: 10.24411/0206−4952−2019−16008

9. Strukturnye osobennosti selektivnykh i neselektivnykh agonistov NOD−retseptorov / Yu. A. Dagil' i dr. // Meditsinskaya immunologiya. 2017. T. 19, № 6. S. 705−714. doi: 10.15789/1563−0625−2017−6−705−714

10. Immunomodulyatsiya: istoriya, tendentsiya razvitiya, sovremennoe sostoyanie i perspektivy / V. M. Man'ko i dr. // Immunologiya. 2002. T. 23, № 3. S. 132−138.

11. Likopid v immunoterapii opukholei: obzor eksperimental'nykh issledovanii / I. G. Kozlov i dr. // Voprosy gematologii/onkologii i immunopatologii v pediatrii. 2011. T. 10, № 2. S. 32−38.

12. Zinchenko M. V. Primenenie likopida i viferona v protsesse luchevogo lecheniya bol'nykh adenokartsinomoi endometriya // Voprosy onkologii. 2006. T. 4, № 52. S. 183−186.

13. Prokhach N. E. Vpliv suprovіdnoї іmunoterapії na yakіst' zhittya khvorikh na rak tіla matki z porushennyami balansu tsitokіnіv // Eksperimental'na і klіnіchna meditsina. 2012. № 2. S. 169−173.

14. Fedenko A. A. Vliyanie nekotorykh immunomodulyatorov na immunnuyu sistemu i perenosimost' ad"yuvantnoi khimio− ili khimioluchevoi terapii u bol'nykh rakom molochnoi zhelezy: avtoref. dis. … kand. med. nauk: 14.00.14. M., 2007. 26 c.

15. Izuchenie vliyaniya preparata "Likopid" na pokazateli perifericheskoi krovi onkologicheskikh bol'nykh (otchet o klinicheskikh ispytaniyakh) / Likopid v onkologii: cb. nauch. st. M., 2008. S. 21−28.

16. Chernetsova L. F., Zotov P. B., Naumov M. M. Immunoterapiya v lechenii rozhistoi infektsii u bol'nykh rasprostranennym rakom molochnoi zhelezy / Likopid v onkologii: cb. nauch. st. M., 2008. S. 48−55.

17. Chernetsova L. F., Zotov P. B. Immunoterapiya soprovozhdeniya likopidom bol'nykh s rasprostranennymi formami zlokachestvennykh novoobrazovanii / Likopid v onkologii: cb. nauch. st. M., 2008. S. 29−38.

18. Zaikov S. V., Shpilevaya S. I. Perspektivy primeneniya immunomodulyatorov muramilpeptidnogo ryada v onkologii // Ratsional'naya farmakoterapiya. 2007. T. 3, № 4. S. 56−59.

19. Immunoterapiya. Rukovodstvo dlya vrachei; pod red. R. M. Khaitova, R. I. Ataullakhanova, A. E. Shul'zhenko. M.: GEOTAR−Media, 2020. 768 s.

20. Taktivin − prirodnyi immunokorrektor. Klinicheskoe primenenie / V. Ya. Arion i dr. // Immunopatologiya, allergologiya, infektologiya. 2007. № 4. S. 11−26.

21. Luss L. V., Martynov−Radushinskii A. A. Vtorichnaya immunnaya nedostatochnost'. Vsegda li nuzhny immunomodulyatory? // Meditsinskii covet. 2014. № 2. S. 40−45. doi: 10.21518/2079−701X−2014−2−40−45

22. T−zavisimye immunoregulyatornye effekty polioksidoniya i imunofana (obzor literatury) / G. Yu. Struchko i dr. // Vestn. Chuvashskogo universiteta. 2010. № 3. S. 140−145.

23. Imunofan − regulyatornyi peptid v terapii infektsionnykh i neinfektsionnykh boleznei / V. V. Lebedev i dr.; pod red. V. I. Pokrovskogo. M.: Praminko, 1998. 119 s.

24. Venediktova M. G. Primenenie "Taktivina" i "Imunofana" pri lechenii bol'nykh adenokartsinomoi endometriya // Eksperimental'naya i klinicheskaya farmakologiya. 2001. T. 64, № 5. S. 46−49.

25. Novikova N. V. Terapiya bol'nykh sarkomoi Kaposhi imunofanom s uchetom sostoyaniya immunnoi sistemy: avtoref. dis. … kand. med. nauk. 14.00.14. M., 2002. 24 s.

26. Grivtsova L. Yu. Aktivator kletochno−oposredovannogo immuniteta − azoksimera bromid. Vozmozhnosti v onkologicheskoi praktike // Paradigmy lekarstvennoi terapii u onkologicheskikh bol'nykh: materialy II nauch.−prakt. onlain−konf. (g. Obninsk, 21−22 maya 2020 g.) Obninsk, 2020. S. 35−47.

27. Vaktsiny "Grippol" i "Vaksigrip" aktivatory ekspressii genov sistemy vrozhdennogo immuniteta v kletkakh ostroi monotsitarnoi leikemii TNR1 / T. M. Sokolova i dr. // Evraziiskii Soyuz Uchenykh. 2016. № 26. C. 61−63.

28. Polyoxidonium® Activates Cytotoxic Lymphocyte Responses Through Dendritic Cell Maturation: Clinical Effects in Breast Cancer / C. Alexia et al. // Frontiers in Immunology. 2019. Vol. 10. URL: https://www.ncbi.nlm.nih.gov /pmc/ articles/PMC6892947/. doi: 10.3389/fimmu.2019.02693

29. Vliyanie immunoad"yuvantov na techenie raka molochnoi zhelezy u bol'nykh s operabel'nym rakom molochnoi zhelezy / M. M. Vasil'eva i dr. // Opukholi zhenskoi reproduktivnoi sistemy. 2018. T. 14, № 4. S. 20−23. doi: 10.17650/1994−4098−2018−14−4−20−23

30. Pruzinec P., Chirun N., Sveikata A. The Safety Profile of Polyoxidonium in Daily Practice: Results from Postauthorization Safety Study in Slovakia // Immunotherapy. 2018. Vol. 10, № 2. P. 131−137. doi: 10.2217/imt−2017−0116

31. Bryuzgin V. V., Platinskii L. V. Rol' tsitokinov v khimioterapii zlokachestvennykh opukholei: praktika primeneniya tsitokinovykh preparatov Refnot® i Ingaron® pri rasprostranennykh opukholevykh protsessakh s mnozhestvennymi metastazami // Sovremennaya onkologiya. 2014. T. 16, № 1. S. 70−75.

32. The role of IFN gamma:in protection against tumor development and cancer immunoediting / H. Ikeda et al. // Cytokine Growth Factor Reviews. 2002. № 13. P. 95−109. doi: 10.1016/s1359−6101(01)00038−7

33. Ling Ni, Jian Lu. Interferon gamma in cancer immunotherapy // Cancer Medicine. 2018. № 7. P. 4509−4516. doi: 10.1002/cam4.1700

34. Intraperitoneal recombinant gamma−interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor−associated effectors and of major histocompatibility antigen expression on tumor cells / P. Allavena et al. // Cancer Research. 1990. Vol. 50, № 22. P. 7318−7323.

35. Interferon−gamma in the first−line therapy of ovarian cancer: a randomized phase III trial / G. H. Windbichler et al. // Br. J. of Cancer. 2000. Vol. 82, № 6. R. 1138−1144. doi: 10.1054/bjoc.1999.1053

36. Khimioterapiya disseminirovannoi melanomy kozhi s vklyucheniem ingarona (γ−interferona). Kliniko−immunologicheskoe issledovanie / M. E. Abramov i dr. // Rossiiskii bioterapevticheskii zhurn. 2009. T. 8. № 1. S. 64−74.

37. Kadagidze Z. G., Slavina E. G., Chertkova A. I. Interferon−gamma v onkologii // Farmateka. 2013. № 17. S. 46−49.

38. Vliyanie rekombinantnogo faktora nekroza opukholi timozin−α1 na angiogenez u bol'nykh disseminirovannoi melanomoi kozhi / I. A. Koroleva i dr. // Meditsinskii sovet. 2017. № 6. C. 146−151.

39. Vliyanie "Refnota" na immunitet u onkologicheskikh bol'nykh / Z. G. Kadagidze i dr. // Farmateka. 2015. № 8. C. 16−20.

40. Rekombinantnyi faktor nekroza opukholi timozin−α1: vliyanie na effektivnost' neoad"yuvantnoi khimioterapii i neoangiogenez pri rake molochnoi zhelezy / L. Yu. Vladimirova i dr. // Voprosy onkologii. 2017. T. 63, № 1. S. 76−81. doi: https://doi.org/10.37469/0507−3758−2017−63−1−76−81

41. Ilyushin A. L., Krasnaya Ya. L., Shabalkin P. I. Rezul'taty otkrytogo sravnitel'nogo issledovaniya v parallel'nykh gruppakh po otsenke effektivnosti i bezopasnosti lekarstvennogo preparata Refnot® (faktor nekroza opukholei − timozin−1 al'fa rekombinantnyi) v lechenii disseminirovannogo troinogo negativnogo raka molochnoi zhelezy // Meditsina. 2019. T. 7, № 3. C. 138−149. doi: 10.29234/2308−9113−2019−7−3−138−149

42. Vliyanie preparatov klassa ERBISOL na produktsiyu tsitokinov i ekspressiyu poverkhnostnykh markerov kletok krovi u zdorovykh donorov i onkologicheskikh patsientov / A. N. Nikolaenko i dr. // Evraziiskii onkologicheskii zhurn. 2016. T. 4, № 1. S. 79−89.

43. Nikolaenko A. N. Farmakologicheskie osobennosti vysokoeffektivnykh lekarstvennykh preparatov novogo pokoleniya klassa "Erbisol®" // Praktikuyuchii lіkar. 2018. T. 7, № 2. S. 5−15.

44. Klinicheskie aspekty ispol'zovaniya preparatov klassa "Erbisol®" v kompleksnoi terapii solidnykh opukholei / Maksimyak G. I. i dr. // Onkologiya. 2010. T. 12, № 3. S. 287−291.

45. Effektivnost' preparata "Erbisol® Ul'trafarm" v kompleksnom lechenii patsientov s metastaticheskimi porazheniyami pecheni / G. I. Maksimyak i dr. // Evraziiskii onkologicheskii zhurn. 2016. T. 4, № 3. S. 696−709.

46. Primenenie preparata "Erbisol Ul'trafarm" v lechenii bol'nykh rakom podzheludochnoi zhelezy / G. I. Maksimyak i dr. // Onkologiya. 2019. T. 21, № 1. S. 36−43. doi: https://doi.org/10.32471/oncology.2663−7928.t−21−1−2019−g.7098

Go on Top